文献速递前列腺癌

成熟局灶治疗——高强度聚焦超声、不可逆电穿孔或冷冻治疗——现状如何——系统综述与Meta分析

Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-10-28

该系统综述与Meta分析纳入2008至2024年间49个局灶治疗队列(冷冻21、HIFU 20、IRE 8),评估肿瘤学与功能结局。汇总总生存率98.0%、癌症特异性生存率99.3%、无转移生存率98.5%,复合失败率14.1%,三种方式间无差异,但结局报告异质且常不完整,需长期随访与标准化报告。

要点

  • 汇总总生存率98.0%、癌症特异性生存率99.3%、无转移生存率98.5%。
  • 活检证实的临床显著前列腺癌(GG≥2)总体22.2%,野内8.9%,野外12.3%。
  • 冷冻、HIFU与IRE在各项结局上无差异,但报告异质且常不完整。

核心结论

  • 冷冻治疗、HIFU和IRE局灶治疗与良好的短期至中期肿瘤学及功能结局相关,但结局报告异质且常不完整,需长期随访与标准化报告以更好定义和报告局灶治疗结局。

研究设计与样本

  • 系统综述与Meta分析,纳入2008至2024年间49个 unique 队列(冷冻治疗21个、HIFU 20个、IRE 8个),描述患者纳入标准、选择工具、治疗参数和监测方案,并汇总总生存、癌症特异性生存、无转移生存、生化进展、活检、二次治疗、性功能和排尿功能结局。

主要发现

  • 中位随访时间范围为6至63个月。
  • 汇总总生存率为98.0%,癌症特异性生存率为99.3%,无转移生存率为98.5%。
  • 汇总生化进展率为每年9.4%。
  • 36/49(73.5%)个队列在局灶治疗后24个月内强制活检,汇总临床显著前列腺癌(GG≥2)率为总体22.2%、野内8.9%、野外12.3%。
  • 汇总二次局灶治疗率为5.0%,根治性治疗率为10.5%,复合失败率为14.1%。

关键数值与推荐

  • 复合失败定义为挽救性全腺体消融、根治性治疗、激素治疗或转为等待观察。
  • 35项报告性功能的研究中,45.7%报告低影响、48.6%报告中度影响、5.7%报告严重影响。
  • 34个报告排尿功能的队列中,97.1%报告低影响。
  • 冷冻治疗、HIFU或IRE在任何结局上均未观察到差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结局报告异质且常不完整。
  • 需要长期随访和标准化报告以更好地定义和报告局灶治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Focal Therapy (FT) is a treatment option for the treatment of limited volume clinically significant prostate cancer (csPCa). We aim to systematically review outcomes of established FT modalities to assess the contemporary baseline and identify gaps in evidence that will aid in further trial and study design. METHODS: We conducted a systematic review and meta-analysis of all primary studies reporting outcomes of FT using cryotherapy, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE). We described patient inclusion criteria, selection tools, treatment parameters, and surveillance protocols, and pooled overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), biochemical progression (BP), biopsy, secondary treatment, sexual, and urinary function outcomes. Composite failure was defined as salvage whole gland ablation, radical treatment, hormonal therapy or transition to watchful waiting. SYNTHESIS: We identified 49 unique cohorts of men undergoing FT between 2008 and 2024 (21 cryotherapy, 20 HIFU, and 8 IRE). Median follow-up ranged from 6 to 63 months. Pooled OS was 98.0%, CSS 99.3%, and MFS 98.5%. Pooled BP was 9.4%/year. Biopsy was mandated post-FT within 24 months in 36/49 (73.5%) cohorts, with pooled csPCa (GG ≥ 2) rates of 22.2% overall, 8.9% infield, and 12.3% outfield. The pooled rate of secondary FT was 5.0%, radical treatment 10.5%, and composite failure 14.1%. Of 35 studies reporting sexual function, 45.7% reported a low, 48.6% moderate, and 5.7% severe impact. For 34 cohorts reporting urinary function, 97.1% reported a low impact. No differences were noted between cryotherapy, HIFU, or IRE in any of the outcomes. CONCLUSION: FT with cryotherapy, HIFU, and IRE is associated with good short-intermediate term oncological and functional outcomes. However, outcome reporting is heterogeneous and often incomplete. Long-term follow-up and standardized reporting are required to better define and report FT outcomes.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tay KJ, Fong KY, Stabile A, et al. Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39468217. doi:10.1038/s41391-024-00911-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。